Possible risk factors include steroid use and chemotherapy, with or without local risk factors such as infection or trauma. Patients should be advised to report any ear pain, discharge from the ear, or an ear infection during denosumab treatment.
In December 2015 the MHRA issued a similar warning with respect to this adverse effect with bisphosphonates.